Search research articles
Contact Us
Filters
Showing results (91-100 of 98) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 98 results.
Blood Cancer Journal
|
January 23, 2016
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
A-L Gagez, E Tuaillon, R Cezar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2005
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
C Foussard, P Colombat, H Maisonneuve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 27, 2010
18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group
X Cahu, C Bodet-Milin, E Brissot, et al.
Bone Marrow Transplantation
|
June 26, 2010
Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients
V Roland, C Bodet-Milin, A Moreau, et al.
Leukemia
|
April 30, 2010
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial
P Moreau, C Hulin, G Marit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 14, 2014
Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center
M Loirat, P Chevallier, C Leux, et al.
Annals of Hematology
|
June 15, 2016
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience
J Bourcier, T Gastinne, C Leux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 21, 2011
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS
R Houot, S Le Gouill, M Ojeda Uribe, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 98) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 98 results.
Blood Cancer Journal
|
January 23, 2016
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
A-L Gagez, E Tuaillon, R Cezar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2005
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
C Foussard, P Colombat, H Maisonneuve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 27, 2010
18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group
X Cahu, C Bodet-Milin, E Brissot, et al.
Bone Marrow Transplantation
|
June 26, 2010
Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients
V Roland, C Bodet-Milin, A Moreau, et al.
Leukemia
|
April 30, 2010
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial
P Moreau, C Hulin, G Marit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 14, 2014
Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center
M Loirat, P Chevallier, C Leux, et al.
Annals of Hematology
|
June 15, 2016
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience
J Bourcier, T Gastinne, C Leux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 21, 2011
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS
R Houot, S Le Gouill, M Ojeda Uribe, et al.
Page
of 10